Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorde...(including factors that could delaydivert...)

Date:8/27/2007

including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the definitive research, development and commercialization agreement relating to early-stage compounds described in this release will result in the discovery, development or commercialization of products. Additionally, the potential products described in this release are subject to the risks and uncertainties involved in the drug discovery and development processes and there can be no guarantee that the potential products described in this release will receive regulatory approval, or that if approved, will be commercially successful. Forward- looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol- Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

'/>"/>

SOURCE Bristol-Myers Squibb Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related biology technology :

1. Mirus Bio, Pfizer enter multimillion-dollar research agreement
2. Pfizer-Pharmacia Fallout Gives Celltech A CEO
3. Sale of Norlight Telecommunications is finalized
4. WARF enters licensing agreements for stem cell products
5. Quick peeks, Clawback Agreements, and the rules of electronic discovery
6. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
7. WARF expands license agreement with Advanced Cell Technology
8. Lucigen Corp. enters global licensing agreement
9. GE Healthcare enters agreement with Canadian health authority
10. New angel capital centered on GenTel agreement with big pharma
11. Prodesse enters patent agreement with Roche